Based on: Low-certainty indirect evidence.

Interferon has been used for many years in various infectious or autoimmune diseases, including SARS-CoV or MERS-CoV infections, among other epidemic coronavirus diseases. Since there is no direct evidence in COVID-19, there has been an attempt to extrapolate information from the earlier diseases. Unfortunately, the evidence regarding the benefit of interferon in those diseases is of very low certainty, so the level of uncertainty for COVID-19 is even higher.

Moreover, as it is an intervention with significant adverse effects and costs, it does not seem like a reasonable option at present, unless it is within the context of a clinical trial to test whether this medication is truly beneficial in COVID-19.

While there are systematic reviews that synthesize the evidence on the effect of interferon in SARS-CoV or MERS-CoV, new information or publications that analyze the information in the context of COVID-19 are likely to appear. To inquire about new evidence or subscribe to it, you can access it through the L.OVE platform, developed by the Epistemonikos Foundation by clicking here.